Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $3.3 million.

  • China Pharma Holdings' Shares Outstanding (Weighted Average) rose 90.06% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 90.06%. This contributed to the annual value of $1.9 million for FY2024, which is 192.15% up from last year.
  • As of Q3 2025, China Pharma Holdings' Shares Outstanding (Weighted Average) stood at $3.3 million, which was down 0.00% from $3.3 million recorded in Q2 2025.
  • China Pharma Holdings' Shares Outstanding (Weighted Average)'s 5-year high stood at $3.3 million during Q2 2025, with a 5-year trough of $87,159 in Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $1.6 million (2024), whereas its average is $1.5 million.
  • Data for China Pharma Holdings' Shares Outstanding (Weighted Average) shows a peak YoY surged of 714.88% (in 2024) over the last 5 years.
  • Over the past 5 years, China Pharma Holdings' Shares Outstanding (Weighted Average) (Quarterly) stood at $94,679 in 2021, then grew by 9.09% to $103,285 in 2022, then soared by 538.07% to $659,033 in 2023, then soared by 192.15% to $1.9 million in 2024, then skyrocketed by 90.06% to $3.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $3.3 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.3 million in Q1 2025.